問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Cardinal Tien Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

Taipei Tzu Chi Hospital (在職)

Division of Endocrinology

Fu Jen Catholic University Hospital (在職)

Division of Endocrinology

Division of Endocrinology

Hualien Tzu Chi Hospital

更新時間：2023-09-19

裴馰
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

裴馰

List

63Cases

2012-03-01 - 2014-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2012-01-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-08-01 - 2019-01-31

Phase III

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes PRONTO-T2D

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    LY900014

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2016-07-31

Phase III

Prospective, randomized, open, and comparative long-acting basal insulin analogue LY2963016 and LANTUS® (LANTUS®) in adults with type 2 diabetes: ELEMENT 5 trial.

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2963016

Participate Sites
7Sites

Terminated7Sites

2013-12-01 - 2015-09-30

Phase III

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus: The ELEMENT 4 Study

  • Condition/Disease

    Type II diabetes

  • Test Drug

    Insulin Basal Analog V (LY2963016)

Participate Sites
9Sites

Terminated9Sites

2019-02-15 - 2021-04-22

Phase III

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2007-05-30 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

  • Condition/Disease

    Diabetic peripheral neuropathy pain

  • Test Drug

    DS-5565

Participate Sites
17Sites

Terminated17Sites

2015-09-01 - 2017-04-04

Phase III

A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 weeks in patients with Type 1 Diabetes Mellitus (EASE2)

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    Jardiance®

Participate Sites
8Sites

Terminated7Sites

陳清助
China Medical University Hospital-Taipei

未分科

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB